{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:09:30Z","timestamp":1788887370743,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.lfs.2017.10.025","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T21:32:26Z","timestamp":1508362346000},"page":"153-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Anti-diabetic potential of peptides: Future prospects as therapeutic agents"],"prefix":"10.1016","volume":"193","author":[{"family":"Marya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Habtemariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2017.10.025_bb0005","first-page":"465","article-title":"The internal secretion of the pancreas By FG banting, MB, and CH Best, BA","volume":"7","author":"Banting","year":"1922","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.lfs.2017.10.025_bb0010","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1021\/ja01132a040","article-title":"The molecular weight of insulin","volume":"74","author":"Harfenist","year":"1952","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.lfs.2017.10.025_bb0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1073\/pnas.12.2.132","article-title":"Crystalline insulin","volume":"12","author":"Abel","year":"1926","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2017.10.025_bb0020","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1126\/science.129.3359.1340","article-title":"Chemistry of insulin","volume":"129","author":"Sanger","year":"1959","journal-title":"Science"},{"key":"10.1016\/j.lfs.2017.10.025_bb0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1210\/endo-8-5-617","article-title":"Recent work on insulin","volume":"8","author":"Best","year":"1924","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2017.10.025_bb0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0021-9258(18)85588-0","article-title":"Glucokinin. A new hormone present in plant tissue preliminary paper","volume":"56","author":"Collip","year":"1923","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1079\/PNS19970051","article-title":"Nature's own pharmacy: the diabetes perspective","volume":"56","author":"Gray","year":"1997","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.lfs.2017.10.025_bb0040","series-title":"3rd International Congress on plant tissue and cell cultures","first-page":"21","article-title":"Extraction of insulin from a plant source","author":"Khanna","year":"1974"},{"key":"10.1016\/j.lfs.2017.10.025_bb0045","series-title":"Google Patents","article-title":"Process for isolation of insulin from plant source","author":"Khann","year":"1976"},{"key":"10.1016\/j.lfs.2017.10.025_bb0050","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1021\/np50018a002","article-title":"Hypoglycemic activity of polypeptide-p from a plant source","volume":"44","author":"Khanna","year":"1981","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.lfs.2017.10.025_bb0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/00007611-198508000-00023","article-title":"Dietary control of diabetes: reality or myth?","volume":"78","author":"Korczowski","year":"1985","journal-title":"South. Med. J."},{"key":"10.1016\/j.lfs.2017.10.025_bb0060","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1016\/S0021-9258(18)45561-5","article-title":"Partial purification and characterization of an insulin-like material from spinach and Lemna gibba G3","volume":"262","author":"Collier","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/092986650601221107153832","article-title":"Jack bean seed coat contains a protein with complete sequence homology to bovine insulin","volume":"6","author":"Oliveira","year":"1999","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.lfs.2017.10.025_bb0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1590\/S0100-879X2002000300004","article-title":"The leaves of green plants as well as a cyanobacterium, a red alga, and fungi contain insulin-like antigens","volume":"35","author":"Silva","year":"2002","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.lfs.2017.10.025_bb0075","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1111\/j.1750-3841.2011.02455.x","article-title":"Food protein-derived bioactive peptides: production, processing, and potential health benefits","volume":"77","author":"Udenigwe","year":"2012","journal-title":"J. Food Sci."},{"key":"10.1016\/j.lfs.2017.10.025_bb0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.niox.2010.04.006","article-title":"Tryptic amaranth glutelin digests induce endothelial nitric oxide production through inhibition of ACE: antihypertensive role of amaranth peptides","volume":"23","author":"de la Rosa","year":"2010","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.lfs.2017.10.025_bb0085","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.foodchem.2012.08.032","article-title":"In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins","volume":"136","author":"Velarde-Salcedo","year":"2013","journal-title":"Food Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0090","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/oxfordjournals.bmb.a072637","article-title":"Diabetes mellitus and free radicals free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications","volume":"49","author":"Wolff","year":"1993","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.lfs.2017.10.025_bb0095","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S2221-1691(11)60051-8","article-title":"Antidiabetic and in vitro antioxidant potential of Hybanthus enneaspermus (Linn) F. Muell in streptozotocin\u2013induced diabetic rats","volume":"1","author":"Patel","year":"2011","journal-title":"Asian Pacific journal of tropical biomedicine"},{"key":"10.1016\/j.lfs.2017.10.025_bb0100","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.2337\/diacare.26.11.3160","article-title":"Follow-up report on the diagnosis of diabetes mellitus: the expert committee on the diagnosis and classifications of diabetes mellitus","volume":"26","author":"Kahn","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2017.10.025_bb0105","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1331\/JAPhA.2009.09076","article-title":"Fate of the beta-cell in the pathophysiology of type 2 diabetes","volume":"49","author":"Campbell","year":"2008","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.lfs.2017.10.025_bb0110","first-page":"489","article-title":"Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function","volume":"70","author":"Mayfield","year":"2004","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.lfs.2017.10.025_bb0115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MED.0b013e3283444ba0","article-title":"Management of diabetes mellitus in the elderly","volume":"18","author":"Chiniwala","year":"2011","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.lfs.2017.10.025_bb0120","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(09)60222-1","article-title":"Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance","volume":"373","author":"Kawamori","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2017.10.025_bb0125","doi-asserted-by":"crossref","first-page":"E182","DOI":"10.1152\/ajpendo.00272.2005","article-title":"Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle","volume":"291","author":"Collier","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2017.10.025_bb0130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","article-title":"Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase\u2013dependent regulation of the orphan nuclear receptor SHP","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2017.10.025_bb0135","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2017.10.025_bb0140","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1532-5415.1996.tb03729.x","article-title":"Individual sulfonylureas and serious hypoglycemia in older people","volume":"44","author":"Shorr","year":"1996","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.lfs.2017.10.025_bb0145","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0895-4356(97)00024-3","article-title":"Rates of hypoglycemia in users of sulfonylureas","volume":"50","author":"Van Staa","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0150","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2337\/diabetes.47.3.345","article-title":"Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes","volume":"47","author":"Fuhlendorff","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2017.10.025_bb0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1262-3636(07)70257-4","article-title":"Meglitinide analogues: a review of clinical data focused on recent trials","volume":"32","author":"Blickl\u00e9","year":"2006","journal-title":"Diabete Metab."},{"key":"10.1016\/j.lfs.2017.10.025_bb0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(11)60207-9","article-title":"Management of type 2 diabetes: new and future developments in treatment","volume":"378","author":"Tahrani","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2017.10.025_bb0165","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X162746","article-title":"Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes","volume":"23","author":"Pratley","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.lfs.2017.10.025_bb0170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.crci.2010.09.004","article-title":"Glucose derived inhibitors of glycogen phosphorylase","volume":"14","author":"Somsak","year":"2011","journal-title":"Comptes Rendus Chimie"},{"key":"10.1016\/j.lfs.2017.10.025_bb0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jpba.2016.06.041","article-title":"Combining biochemical with 1 H NMR-based metabolomics approach unravels the antidiabetic activity of genipin and its possible mechanism","volume":"129","author":"Shen","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.lfs.2017.10.025_bb0180","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0196-9781(97)00378-1","article-title":"Xenin-a review","volume":"19","author":"Feurle","year":"1998","journal-title":"Peptides"},{"key":"10.1016\/j.lfs.2017.10.025_bb0185","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1677\/JOE-10-0085","article-title":"Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety","volume":"207","author":"Taylor","year":"2010","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0190","doi-asserted-by":"crossref","first-page":"19842","DOI":"10.1074\/jbc.M110.129304","article-title":"Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism","volume":"285","author":"Wice","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152818","article-title":"Biological activity and antidiabetic potential of C-terminal octapeptide fragments of the gut-derived hormone xenin","volume":"11","author":"Martin","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.lfs.2017.10.025_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152818","article-title":"Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin","volume":"11","author":"Martin","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.lfs.2017.10.025_bb0205","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.14202\/vetworld.2016.1152-1156","article-title":"Effect of boiling on the antidiabetic property of enzyme treated sheep milk casein","volume":"9","author":"Jan","year":"2016","journal-title":"Veterinary World"},{"key":"10.1016\/j.lfs.2017.10.025_bb0210","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3945\/jn.113.174912","article-title":"A whey protein hydrolysate promotes insulinotropic activity in a clonal pancreatic \u03b2-cell line and enhances glycemic function in ob\/ob mice","volume":"143","author":"Gaudel","year":"2013","journal-title":"J. Nutr."},{"key":"10.1016\/j.lfs.2017.10.025_bb0215","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.30.1_supplement.125.6","article-title":"Antidiabetic effect of black bean peptides through reduction of glucose absorption and modulation of SGLT1, GLUT2 and DPP-IV in in vitro and in vivo models","volume":"30","author":"Mojica","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2017.10.025_bb0220","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/jf404539y","article-title":"Characterization of antidiabetic and antihypertensive properties of canary seed (Phalaris canariensis L.) peptides","volume":"62","author":"Estrada-Salas","year":"2014","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0225","first-page":"1","article-title":"Influence of cowpea (Vigna unguiculata) peptides on insulin resistance","volume":"3","author":"Barnes","year":"2015","journal-title":"J Nutr Health Food Sci"},{"key":"10.1016\/j.lfs.2017.10.025_bb0230","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1620\/tjem.236.71","article-title":"Hypoglycemic, hypolipidemic and antioxidant effects of peptides from red deer antlers in streptozotocin-induced diabetic mice","volume":"236","author":"Jiang","year":"2015","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.lfs.2017.10.025_bb0235","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00394-008-0710-2","article-title":"Bioactive peptides and proteins from foods: indication for health effects","volume":"47","author":"M\u00f6ller","year":"2008","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.lfs.2017.10.025_bb0240","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1039\/C4RA12943A","article-title":"Antioxidant and antidiabetic activities of peptides isolated from a hydrolysate of an egg-yolk protein by-product prepared with a proteinase from Asian pumpkin (Cucurbita ficifolia)","volume":"5","author":"Zambrowicz","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.lfs.2017.10.025_bb0245","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/10942912.2010.503357","article-title":"Anti-oxidant, anti-diabetic, and anti-hypertensive effects of extracted phenolics and hydrolyzed peptides from barley protein fractions","volume":"15","author":"Alu'datt","year":"2012","journal-title":"Int. J. Food Prop."},{"key":"10.1016\/j.lfs.2017.10.025_bb0250","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.foodchem.2012.06.088","article-title":"Anti-diabetic activity peptides from albumin against \u03b1-glucosidase and \u03b1-amylase","volume":"135","author":"Yu","year":"2012","journal-title":"Food Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0255","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jfda.2013.05.009","article-title":"Studies on the extraction of pumpkin components and their biological effects on blood glucose of diabetic mice","volume":"21","author":"Jin","year":"2013","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.lfs.2017.10.025_bb0260","doi-asserted-by":"crossref","first-page":"8895","DOI":"10.1021\/jf200678q","article-title":"Hypoglycemic effects and biochemical mechanisms of oat products on streptozotocin-induced diabetic mice","volume":"59","author":"Shen","year":"2011","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2254-609X.100007","article-title":"Peptides derived from oats improve insulin sensitivity and lower blood glucose in streptozotocin-induced diabetic mice","volume":"4","author":"Zhang","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.lfs.2017.10.025_bb0270","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.foodchem.2015.05.120","article-title":"Enzyme-assisted extraction and identification of antioxidative and \u03b1-amylase inhibitory peptides from Pinto beans (Phaseolus vulgaris cv. Pinto)","volume":"190","author":"Ngoh","year":"2016","journal-title":"Food Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/md15040088","article-title":"Marine peptides as potential agents for the management of type 2 diabetes mellitus\u2014a prospect","volume":"15","author":"Xia","year":"2017","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.lfs.2017.10.025_bb0280","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s00125-004-1444-1","article-title":"Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes","volume":"47","author":"Anis","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2017.10.025_bb0285","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/cmdc.201500140","article-title":"Synthesis and evaluation of a series of long-acting glucagon-like peptide-1 (GLP-1) pentasaccharide conjugates for the treatment of type 2 diabetes","volume":"10","author":"Irwin","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.lfs.2017.10.025_bb0290","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/dom.12483","article-title":"Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide","volume":"17","author":"Patterson","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2017.10.025_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141549","article-title":"Esculentin-2CHa-related peptides modulate islet cell function and improve glucose tolerance in mice with diet-induced obesity and insulin resistance","volume":"10","author":"Ojo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2017.10.025_bb0300","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2017.10.025_bb0305","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2017.10.025_bb0310","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1073\/pnas.1601653113","article-title":"Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery","volume":"113","author":"Yang","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2017.10.025_bb0315","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2017.10.025_bb0320","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2017.10.025_bb0325","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1590\/S0100-879X2003000900004","article-title":"A protein with amino acid sequence homology to bovine insulin is present in the legume Vigna unguiculata (cowpea)","volume":"36","author":"Venancio","year":"2003","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.lfs.2017.10.025_bb0330","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1590\/S1677-04202003000200002","article-title":"Plant insulin or glucokinin: a conflicting issue","volume":"15","author":"Xavier-Filho","year":"2003","journal-title":"Braz. J. Plant Physiol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0335","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1476-5381.2010.00677.x","article-title":"\u03b2-adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKA","volume":"160","author":"Stuen\u00e6s","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0340","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbr.2007.01.008","article-title":"Xenin reduces feed intake by activating the ventromedial hypothalamus and influences gastrointestinal transit rate in chicks","volume":"179","author":"Cline","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2017.10.025_bb0345","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbr.2013.12.005","article-title":"Impaired suppression of feeding by the gut hormone xenin in type I interleukin-1 receptor-deficient mice","volume":"261","author":"Kim","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2017.10.025_bb0350","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2337\/db08-0260","article-title":"Xenin, a gastrointestinal peptide, regulates feeding independent of the melanocortin signaling pathway","volume":"58","author":"Leckstrom","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2017.10.025_bb0355","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/cen.12114","article-title":"Appetite-regulating hormones from the upper gut: disrupted control of xenin and ghrelin in night workers","volume":"79","author":"Schiavo-Cardozo","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0360","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/JOE-13-0617","article-title":"Characterisation of the biological activity of xenin-25 degradation fragment peptides","volume":"221","author":"Martin","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0365","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00592-014-0681-0","article-title":"Xenin-25 [Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential","volume":"52","author":"Gault","year":"2015","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0370","doi-asserted-by":"crossref","first-page":"G301","DOI":"10.1152\/ajpgi.00383.2013","article-title":"Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes","volume":"306","author":"Chowdhury","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0375","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2017.10.025_bb0380","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jcp.2006.043232","article-title":"Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1","volume":"61","author":"Ranganath","year":"2008","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0385","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1530\/JOE-12-0502","article-title":"Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides","volume":"217","author":"Liu","year":"2013","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0390","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nucmedbio.2003.07.003","article-title":"Pharmacokinetics and tumor retention of 125 I-labeled RGD peptide are improved by PEGylation","volume":"31","author":"Chen","year":"2004","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.lfs.2017.10.025_bb0395","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0169-409X(01)00231-9","article-title":"Oral drug absorption enhancement by chitosan and its derivatives","volume":"52","author":"Thanou","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2017.10.025_bb0400","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.lfs.2017.10.025_bb0405","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1021\/jm030630m","article-title":"Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes","volume":"47","author":"Knudsen","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0410","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/bc049735+","article-title":"Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1","volume":"16","author":"Lee","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.lfs.2017.10.025_bb0415","unstructured":"Valicherla G. R., Mohammed R., Gupta A. P., Syed A. A., G.J. R., Plasma Protein Binding, Pharmacokinetics, and Bioavailability Assessment of a Novel Potent Antidiabetic Peptide, PSTv8 in Rats Using Liquid Chromatography Tandem Mass Spectrometry. Central Drug Research Institute."},{"key":"10.1016\/j.lfs.2017.10.025_bb0420","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0169-409X(97)00045-8","article-title":"Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies","volume":"27","author":"Pauletti","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2017.10.025_bb0425","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1021\/mp300009u","article-title":"A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine5-enkephalin, to the brain","volume":"9","author":"Lalatsa","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lfs.2017.10.025_bb0430","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJN.S596","article-title":"Drug delivery and nanoparticles: applications and hazards","volume":"3","author":"De Jong","year":"2008","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2017.10.025_bb0435","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/187221108786241679","article-title":"Microemulsions: a novel approach to enhanced drug delivery","volume":"2","author":"Talegaonkar","year":"2008","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.lfs.2017.10.025_bb0440","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2146\/ajhp150174","article-title":"Insulin glargine 300 units\/mL: a new basal insulin product for diabetes mellitus","volume":"73","author":"Clements","year":"2016","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.lfs.2017.10.025_bb0445","series-title":"Diabetes","first-page":"A260","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analog, in subjects with and without renal impairment","author":"Marbury","year":"2014"},{"key":"10.1016\/j.lfs.2017.10.025_bb0450","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species","volume":"104","author":"Jensen","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2017.10.025_bb0455","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.drudis.2013.05.011","article-title":"Future directions for peptide therapeutics development","volume":"18","author":"Kaspar","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2017.10.025_bb0460","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrd1108","article-title":"The impact of drug-induced QT interval prolongation on drug discovery and development","volume":"2","author":"Fermini","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2017.10.025_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.59.090506.155819","article-title":"The FDA critical path initiative and its influence on new drug development","volume":"59","author":"Woodcock","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.lfs.2017.10.025_bb0470","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.phrs.2016.09.029","article-title":"Efficacy and risk profile of anti-diabetic therapies: conventional vs traditional drugs\u2014a mechanistic revisit to understand their mode of action","volume":"113","author":"Gupta","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2017.10.025_bb0475","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2017.03.015","article-title":"Novel strategies in the oral delivery of antidiabetic peptide drugs \u2013 insulin, GLP 1 and its analogs","volume":"115","author":"Ismail","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.lfs.2017.10.025_bb0480","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.lfs.2017.10.025_bb0485","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.2337\/dc11-s231","article-title":"Long-acting glucagon-like peptide 1 receptor agonists","volume":"34","author":"Garber","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2017.10.025_bb0490","series-title":"Beyond Metformin: Safety Considerations in the Decision-making Process for Selecting a Second Medication for Type 2 Diabetes Management","author":"Cefalu","year":"2014"},{"key":"10.1016\/j.lfs.2017.10.025_bb0495","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2337\/dc12-0709","article-title":"The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2017.10.025_bb0500","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.clinthera.2015.08.022","article-title":"Subcutaneous bioavailability of taspoglutide at 3 different injection sites in healthy overweight\/obese subjects","volume":"37","author":"Sturm-Pellanda","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.lfs.2017.10.025_bb0505","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jff.2017.03.029","article-title":"The potential roles of Pinto bean (Phaseolus vulgaris cv. Pinto) bioactive peptides in regulating physiological functions: protease activating, lipase inhibiting and bile acid binding activities","volume":"33","author":"Ngoh","year":"2017","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.lfs.2017.10.025_bb0510","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jff.2017.03.042","article-title":"Protein extract from the fruit pulp of Momordica dioica shows anti-diabetic, anti-lipidemic and antioxidant activity in diabetic rats","volume":"33","author":"Poovitha","year":"2017","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.lfs.2017.10.025_bb0515","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.regpep.2006.03.006","article-title":"Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP (1\u201316) and (Pro 3) GIP (1\u201316)","volume":"135","author":"Irwin","year":"2006","journal-title":"Regul. Pept."},{"key":"10.1016\/j.lfs.2017.10.025_bb0520","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.lfs.2017.10.025_bb0525","first-page":"396","article-title":"Potential antioxidant and antidiabetic activities of Kayu Kuning (Arcangelisia Flava)","volume":"9","author":"Wahyudi","year":"2016","journal-title":"Agric. Agric. Sci. Procedia"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320517305398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320517305398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:46:25Z","timestamp":1788885985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320517305398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":105,"alternative-id":["S0024320517305398"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2017.10.025","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-diabetic potential of peptides: Future prospects as therapeutic agents","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2017.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}